1. Department: HBC

Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process

Written by Posted on Less than 0 min read

By Bryce Platt, PharmD

Summer officially starts this weekend!

Consider doing a few of your lifting sets (or work meetings) outside.

The healthier you are, the longer you’ll be able to read our news roundups, so everybody wins!

In this issue:

Extra: The Process of Filling a Pharmacy Prescription

P.S. Join my nearly 36,000 LinkedIn followers for valuable daily posts at 9 a.m. ET.
Read more »

© 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 44
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Media & Marketing

When Access Tightens, Prior Authorization Execution Becomes the Differentiator

Today’s guest post comes from Megan Wetzel, Vice President of Product, Access and Affordability at CoverMyMeds. Megan examines how prior authorization execution has become a strategic differentiator for biopharma brands as formulary changes and expanding utilization management put more pressure on access. She argues that building consistent, scalable prior auth execution can reduce therapy delays, […]
2 min read
0
  1. Data & Insights

Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization

Today’s guest post comes from Sean Wagner, VP of Client Partnerships and Carolyn Zele, Advisor, Solution Consulting at MMIT. Sean and Carolyn argue that planning for a successful drug launch must begin early—often well before Phase III. In this article, they present a six-step framework to help manufacturers align clinical development with payer expectations, patient […]
2 min read
0
  1. Corporate Strategy

A System of Record, or a System of Learning?

Today’s guest post comes from Scott Filosi, Chief Commercial Officer at Valeris. Scott explores how patient access organizations can move beyond simply tracking the patient journey to using real-time insights to improve it. He argues that connecting commercial strategy, market access, payer intelligence, and patient services can speed access to therapy, improve decision-making, and enhance […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI

Spring has officially arrived at Drug Channels’ worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, dive into this month’s curated crop of noteworthy news: The patient experience at PBM-affiliated specialty pharmacies New evidence of profit shifting in vertically integrated Part D businesses The growing gap between non-profit hospitals’ public mission and financial […]
2 min read
0
  1. Data & Insights

Unlocking the Gate: The Critical First 24 Hours of Patient Hub Engagement

Today’s guest post comes from Kristine McGaughey, Vice President, Implementation at ConnectiveRx and Sam Blake, SVP, Hub Product at ConnectiveRx. Sam and Kristine discuss the importance of the first 24 hours of a patient’s engagement with a hub services program. They outline five reasons why two components—patient enrollment and successful benefits verification—dictate the effectiveness of […]
2 min read
0
  1. Data & Insights

Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead. Click here to see the original post from February 2025. ICYMI, the largest three pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are using vertical integration to build significant market positions in businesses beyond drug […]
3 min read
0
  1. Data & Insights

Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand

Today’s guest post comes from Michael Harris, Vice President of Patient Support Services Strategy at Valeris. Michael explores the rise of medical benefit maximizers as a new—and often overlooked—force shaping patient access. He outlines how these strategies can erode access, absorb support dollars, and introduce hidden risks for brands. To learn more about Valeris’ technology […]
2 min read
0
  1. Shopper & Customer

Direct-to-Consumer Models: Why They’re Expanding and Where They Deliver the Most Impact

Today’s guest post comes from Jordan Armstrong, Vice President of Business Development at AssistRx. Jordan discusses the uptick in direct-to-consumer (DTC) models for life sciences organizations looking to navigate market challenges and improve patient access. He goes on to describe some potential risks and complexities associated with these models. To learn about AssistRx’s technology solutions […]
2 min read
0
  1. Data & Insights

Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight

Today’s guest post comes from Stephen Hom, Co-Founder, EVP & Chief Operating Officer of RIS Rx. Drawing on RIS Rx’s proprietary data and case studies, Stephen highlights patterns that can undermine patient support program effectiveness. He argues that a more data-driven approach can help manufacturers identify hidden risks, improve program performance, and ensure that affordability […]
2 min read
0
  1. Corporate Strategy

Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains

By Bryce Platt, PharmD Summer’s in full swing, but the drug channel didn’t take a break. What better way to spend the summer than reading about new pharmacy resources in the Drug Channels News Roundup? In this issue: The New Biosimilar Launch Playbook Factors Adding to Part D Cost Trends Rural vs. Non-rural 340B Hospitals […]
2 min read
0
  1. Data & Insights

Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment

Today’s guest post is from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx. Divya shares new GoodRx data showing that out-of-pocket costs at the pharmacy counter remain a primary barrier to medication adherence. Despite the availability of manufacturer-sponsored support programs, many patients still abandon their prescriptions due to high costs. To learn about GoodRx’s prescription […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family

I’m pleased to introduce a new recurring feature from Bryce Platt, DCI’s new Director. Each month, Bryce will highlight some of his most notable LinkedIn posts—for those of you who don’t follow him or can’t keep up with his prolific stream of drug channel graphics. Best, Adam Welcome to my first Drug Channels post! Yes, […]
3 min read
0
  1. Media & Marketing

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth. For those who prefer watching to reading, I asked AI to turn our latest 340B analysis into a tidy little video. Let me know what you think of this format and whether […]
2 min read
0
  1. Department: HBC

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments

Three’s still company in the world of pharmacy benefit managers. For 2024, nearly 80% of all equivalent prescription claims were processed by three familiar companies: the CVS Caremark business of CVS Health, the Express Scripts business of Cigna, and the Optum Rx business of UnitedHealth Group. The names haven’t changed, but shifting relationships and contract […]
2 min read
0
  1. Trends & External Forces

The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble

As I highlighted last week, we are entering the Net Pricing Drug Channel (NPDC) era—a market environment in which net prices, not list prices, determine access, economics, and competitive strategy. This shift represents a structural change in how value is created and captured across the U.S. drug channel. The NPDC will: Reward simpler pricing models […]
3 min read
0
  1. Trends & External Forces

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs

For 2026, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)—have once again excluded hundreds of drugs from their standard formularies. Our updated counts appear below. The 2026 lists highlight how formulary preferences for Humira and Stelara are dominated by private-label biosimilars affiliated with the same […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2026 Video Webinar Series

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI), for three new video webinars during 2026. These live, interactive events are designed for executives who need timely insight into the rapidly changing U.S. drug channel. They will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. Register Now […]
4 min read
0
  1. Data & Insights

Hubs: The Bridge Between Patients and Providers

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health. Josh examines the central role that hubs play in connecting patients, providers, and other stakeholders. He shares how hubs, by gathering and interpreting real-world insights, can help improve access, adherence, and the overall patient experience. […]
2 min read
0
  1. Data & Insights

Beyond Throughput: Building Reverification Strategies That Safeguard Access

Today’s guest post comes from Gregory Morris, Chief Strategy Officer at CareMetx. Gregory examines how Annual Reverification (AR) processes must evolve in response to changing payer dynamics and increasing benefit complexity. Rather than focusing solely on throughput and operational efficiency, he argues for the importance of more nuanced strategies that help ensure patients maintain access […]
2 min read
0
  1. Data & Insights

Hubs, AI, and the New Era of Revenue Protection in Patient Access

Today’s guest post comes from Steve Randall, Chief Technology Architect at ConnectiveRx. Steve examines how artificial intelligence (AI) is reshaping the role of patient support hubs in the specialty drug ecosystem. As policy, payer, and gross-to-net pressures mount, he argues that the hub model must evolve from a service function into a revenue-protection strategy—one that […]
2 min read
0
Next